

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide

– Contributions include USD 1 million to the COVID-19 Solidarity Response Fund for WHO –

An Important Message from Shinjiro Sato, President and CEO, Terumo Corporation

TOKYO, JAPAN – April 22, 2020 – As the world joins together to support healthcare workers and others on the front lines providing critical care to patients, Terumo Corporation (TSE: 4543) is donating USD 2.4 million in cash and products to support the novel coronavirus disease (COVID-19) relief efforts worldwide – including a USD 1 million donation to the [COVID-19 Solidarity Response Fund for WHO](#).



The Solidarity Response Fund, a global effort to support the [World Health Organization](#) (WHO), established by the UN Foundation and the Swiss Philanthropy Foundation, assists countries across the globe in the prevention, detection and response to the COVID-19 pandemic. Donations support the WHO and its partners' diligent efforts to track and understand the spread of COVID-19, help ensure patients get the care they need, and provide frontline workers with essential supplies and information. The fund also strives to accelerate research and development of vaccines, tests and treatments.

“We have the privilege of working in the healthcare industry, which comes with deep responsibility – particularly for those on the front lines each day, fighting the good fight – to ensure patients get the care they need, and to be armed with the resources and supplies to make this happen,” said Shinjiro Sato, President & CEO, Terumo Corporation. “We all can play an important role in protecting everyone’s health and safety, and through these efforts, we are honored to do our part.”

In addition to this donation to the Solidarity Response Fund, Terumo has already made cash and product contributions totaling USD 1.4 million, including donating a large number of digital thermometers and vital cardiopulmonary support systems (ECMO, or Extracorporeal Membrane Oxygenation) to medical institutions.

As one of the largest global medical technology companies, Terumo provides life-supporting and lifesaving products so that healthcare professionals can continue to serve their patients worldwide. These include hardware used to treating COVID-19 patients, such as ECMO and apheresis systems, to medical products essential for daily clinical practice. Furthermore, Terumo continues to work with healthcare professionals and legislators to increase access to therapies that can impact COVID-19. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Past Announcements on COVID-19

[Terumo BCT’s Mirasol Shows Efficacy Against Virus Causing COVID-19 in Plasma and Platelets \(April 17, 2020\)](#)

[Terumo BCT and Marker Therapeutics Received the First Device FDA Emergency Use Authorization \(EUA\) to Treat Acute Respiratory Failure in COVID-19 Patients \(April 10, 2020\)](#)

[Terumo Statement on COVID-19 \(April 3, 2020\)](#)

[Terumo Statement Regarding Production \(COVID-19\) \(March 12, 2020\)](#)

[Terumo Responds to the Novel Coronavirus Outbreak in China \(February 4, 2020\)](#)

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.

###

Powered by



in support of the **WORLD HEALTH ORGANIZATION**